Belite Bio, Inc. (BLTE)
175.50
-7.66
(-4.18%)
USD |
NASDAQ |
Sep 10, 13:49
Belite Bio Enterprise Value : 7.096B for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | 7.096B |
| September 08, 2026 | 7.487B |
| September 04, 2026 | 7.517B |
| September 03, 2026 | 6.610B |
| September 02, 2026 | 6.190B |
| September 01, 2026 | 6.031B |
| August 31, 2026 | 5.991B |
| August 28, 2026 | 5.830B |
| August 27, 2026 | 6.043B |
| August 26, 2026 | 6.030B |
| August 25, 2026 | 6.231B |
| August 24, 2026 | 6.118B |
| August 21, 2026 | 6.206B |
| August 20, 2026 | 6.242B |
| August 19, 2026 | 6.508B |
| August 18, 2026 | 6.267B |
| August 17, 2026 | 6.293B |
| August 14, 2026 | 6.276B |
| August 13, 2026 | 6.417B |
| August 12, 2026 | 6.926B |
| August 11, 2026 | 6.872B |
| August 10, 2026 | 6.456B |
| August 07, 2026 | 6.286B |
| August 06, 2026 | 6.191B |
| August 05, 2026 | 6.103B |
| Date | Value |
|---|---|
| August 04, 2026 | 6.054B |
| August 03, 2026 | 5.954B |
| July 31, 2026 | 6.108B |
| July 30, 2026 | 6.160B |
| July 29, 2026 | 5.859B |
| July 28, 2026 | 6.001B |
| July 27, 2026 | 6.100B |
| July 24, 2026 | 5.896B |
| July 23, 2026 | 6.014B |
| July 22, 2026 | 6.048B |
| July 21, 2026 | 6.207B |
| July 20, 2026 | 5.875B |
| July 17, 2026 | 5.764B |
| July 16, 2026 | 5.788B |
| July 15, 2026 | 5.740B |
| July 14, 2026 | 5.627B |
| July 13, 2026 | 5.641B |
| July 10, 2026 | 5.734B |
| July 09, 2026 | 5.891B |
| July 08, 2026 | 5.854B |
| July 07, 2026 | 6.071B |
| July 06, 2026 | 5.923B |
| July 02, 2026 | 5.625B |
| July 01, 2026 | 5.451B |
| June 30, 2026 | 5.921B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -43.60M |
| CorMedix, Inc. | 519.23M |
| Eloxx Pharmaceuticals, Inc. | 4.917M |
| Cannabis Global, Inc. | -- |
| Breakthrough Chemistry, Inc. | 1.506M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -28.41M |
| Total Expenses (Quarterly) | 28.41M |
| EPS Diluted (Quarterly) | -0.7071 |
| Earnings Yield | -1.56% |
| Normalized Earnings Yield | -1.558 |